Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04585477
Title Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Stanford University
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST